Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
Noosa News22 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
General17 hours agoIran’s currency at record low as tensions run high
-
General16 hours agoLabor to pledge $2.3 billion to subsidise home batteries
-
General22 hours ago307,000 Voices | The Spectator Australia